EBMT 2016 | The future of treating acute leukemias
Giovanni Martinelli, MD, from the University of Bologna, Bologna, Italy discusses how inotuzumab ozogamicin is now used as a frontline therapy in adult acute lymphoblastic leukemia (ALL). According to Prof Martinelli, this means that patients can be treated with more intensive chemotherapy later on or receive a bone marrow transplantation to consolidate the therapy. The future will be without chemotherapy according to Prof Martinelli.
Recorded at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.
Get great new content delivered to your inboxSign up